FiercePharmaAsia—China’s drug policy overhaul, top generic drugmakers, BI’s China biologics plant
FiercePharma | May 19, 2017
Welcome to this week's FiercePharmaAsia report, which includes China's new wave of policy changes aimed to streamline clinical trials and drug approvals, a special report on the top 15 generic drugmakers by 2016 revenue, a new biologics plant by Boehringer Ingelheim in Shanghai and more.